key: cord-0905774-0lmtdsie
authors: Medina-Pestana, José; Cristelli, Marina Pontello; Viana, Laila Almeida; Foresto, Renato Demarchi; Requião-Moura, Lucio R.; Tedesco-Silva, Helio; Covas, Dimas Tadeu
title: Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients
date: 2021-07-20
journal: Transplantation
DOI: 10.1097/tp.0000000000003901
sha: 0242314e7694cc1df2da9be5249e65463edaf401
doc_id: 905774
cord_uid: 0lmtdsie

nan

measures; (2) inform consent discussion and signature;

(3) registration of the patient in the electronic medical records of the institution; (4) blood sampling for serology followed by vaccination, and a reminder of the scheduled second dose. All employees of the institution were invited to participate in the vaccination campaign, and >300 professionals volunteered for the activity, including students from different universities.

The study was approved by the local ethics committee, registered at ClinicalTrials.gov, NCT04801667, and all patients signed an informed consent form. At day 28, a prespecified questionnaire was obtained to capture adverse reactions to the vaccine or newly diagnosed SARS-CoV-2 infection. Sample size for the immunogenicity cohort (942 patients seronegative for immunoglobulin [Ig]G anti-SARS-CoV-2 before the first dose) was calculated using the age distribution and seroconversion rate (71%) of the phase 3 study, 1 with 95% confidence interval and an absolute error of 10%. Antibody response at day 28 was assessed using the AdviseDx SARS-CoV-2 IgG II assay (Abbot Laboratories, IL). Values >50 AU/mL were considered positive. 3 Characteristics and outcomes of the study population (n = 3354) are in Table 1 . The patients were predominantly male, median age of 52 (interquartile range [IQR], 44-60) y, low prevalence of diabetes mellitus, and median time posttransplant of 7 (IQR, 3-12) y. Seroprevalence of IgG anti-SARS-CoV-2 nucleocapsid protein at D0 was 3.6%, and these seropositive patients at the time of vaccine were excluded for the analysis of the antibody responses. Among the seronegative patients at D0, there were 1012 individuals randomly selected for the immunogenicity analysis. The other patients did not have any testing performed after the vaccination. After the first vaccine dose, 61 (1.8%) patients had COVID-19 confirmed by reverse transcription-polymerase chain reaction or antigen test at a median time of 12 (IQR, 8-16) d. Of them, 44 (72%) required hospitalization and 16 (26%) died 14-49 d after the first vaccine dose.

The most common adverse reaction was local pain/tenderness (11%). Systemic symptoms occurred in 5% or less of the patients; no severe adverse reaction was observed. There was only 1 episode of acute cellular rejection (Banff IB) 6 d after vaccination in a patient with documented nonadherence that showed partial recovery of renal function after treatment with methylprednisone and antithymocyte globulin.

Seroconversion 28 d after the first dose was 15.2% (95% confidence interval, 12.9%-17.5%), with median IgG value of 477 AU/mL (IQR, 123-1705). Patients aged >60 y or those who underwent combined kidney-pancreas transplants had lower seroconversion than those aged <60 y and underwent isolated kidney transplants.

The potential advantage of the traditional inactivated vaccines, the induction of a broader polyclonal immune response, 4 was not associated with a higher seroconversion rate compared with the newer RNA-based COVID-19 vaccines. 5 In this ongoing prospective study, there was no obvious clinical impact after the first dose, as 

Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. [Epub ahead of print

The full spectrum of COVID-19 development and recovery among kidney transplant recipients

AdviseDx SARS-CoV-2 IgG II instructions for use

SARS-CoV-2 vaccine development: where are we?

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

This work would not be possible without the provision of the vaccines, coordinated by Ricardo Palacios, MD, PhD, and Roberta Piorelli, MD, from Instituto Butantan, the volunteer work of almost 300 students and professionals of the Hospital do Rim and other medical institutions in São Paulo during vaccination, and the valuable contribution of our biochemist Elizabeth França Lucena, BA, who conducted all the laboratory analysis.